NCT01780662 2021-10-28
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
National Cancer Institute (NCI)
National Cancer Institute (NCI)